Amgen Competitors and Similar CompaniesClear all
Abbott's competitors and similar companies include PRA Health Sciences, Viatris, Allergan, Novo Nordisk, AstraZeneca, Biogen, Avantor, Hospira, AbbVie, Coherus BioSciences and Galenica.
 PRA Health Sciences PRA Health Sciences is a contract research organization that provides outsourced clinical development services to the biotechnology and pharmaceutical industries. |  Viatris Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products. |  Allergan Allergan is a healthcare company focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products. |  Novo Nordisk Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products. |  AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. |  Avantor Avantor is a company that provides chemical materials and consumables, lab equipment and instrumentation, as well as procurement and production services. |  AbbVie AbbVie is a pharmaceutical company engaged in the research, development, manufacturing, commercialization, and sale of medicines and therapies. |  Coherus BioSciences Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments. |  Galenica Galenica is a provider of healthcare services and products operating in two business segments: Products & Care, Logistics & IT. | |||
Founding Date | Founding Date 1894 | Founding Date 1976 | Founding Date 2020 | Founding Date 1948 | Founding Date 1923 | Founding Date 1999 | Founding Date 1978 | Founding Date 1904 | Founding Date 2004 | Founding Date 2013 | Founding Date 2010 | Founding Date 1927 |
Type | Type Public | Type Subsidiary | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Abbott Park, US HQ Tiranë, AL Buenos Aires, AR Yerevan, AM Doncaster, AU East Brisbane, AU Macquarie Park, AU see more | Locations Raleigh, US HQ Buenos Aires, AR Haymarket, AU South Yarra, AU Minsk, BY Mechelen, BE São Paulo, BR see more | Locations Canonsburg, US HQ Carole Park, AU Millers Point, AU Campos Dos Goytacazes, BR São Paulo, BR Sofia, BG Toronto, CA see more | Locations Dublin, IE HQ Buenos Aires, AR Roseville, AU Machelen, BE Guarulhos, BR Las Condes, CL Bogotá, CO see more | Locations Bagsværd, DK HQ Tirana, AL Boufarik, DZ Hydra, DZ Tizi Ouzou, DZ Buenos Aires, AR North Sydney, AU see more | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Haedo, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | Locations Lake Forest, US HQ | Locations North Chicago, US HQ Alger, DZ Buenos Aires, AR Mascot, AU Wien, AT Wavre, BE Sarajevo, BA see more | Locations Redwood City, US HQ Camarillo, US | Locations Bern, CH HQ | |
Employees | Employees 114,0001% decrease | Employees 18,1003% increase | Employees 38,0003% increase | Employees 17,658 | Employees 69,260 | Employees 89,900 | Employees 7,57013% decrease | Employees 14,500 | Employees 5,309 | Employees 50,000 | Employees 30615% decrease | Employees 7,9551% increase |
Valuation ($) | Valuation ($) 196.1 b | Valuation ($) N/A | Valuation ($) 13.7 b | Valuation ($) N/A | Valuation ($) 599.3 b | Valuation ($) 2.7 b | Valuation ($) 27.5 b | Valuation ($) 17.3 b | Valuation ($) N/A | Valuation ($) 343.2 b | Valuation ($) 117.5 m | Valuation ($) N/A |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) $40.1b (FY, 2023) | Revenue (est.) $3.2b (FY, 2020) | Revenue (est.) $15.4b (FY, 2023) | Revenue (est.) $16.1b (FY, 2019) | Revenue (est.) kr232.3b (FY, 2023) | Revenue (est.) $45.8b (FY, 2023) | Revenue (est.) $9.8b (FY, 2023) | Revenue (est.) $7b (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $54.3b (FY, 2023) | Revenue (est.) $257.2m (FY, 2023) | Revenue (est.) CHF3.7b (FY, 2023) |
Cost of goods | Cost of goods $18b (FY, 2023) | Cost of goods $2.3b (FY, 2020) | Cost of goods $9b (FY, 2023) | Cost of goods $2.5b (FY, 2019) | Cost of goods kr30.8b (FY, 2023) | Cost of goods $7.2b (FY, 2023) | Cost of goods $2.5b (FY, 2023) | Cost of goods $4.6b (FY, 2023) | Cost of goods N/A | Cost of goods $20.4b (FY, 2023) | Cost of goods $159m (FY, 2023) | Cost of goods CHF2.7b (FY, 2023) |
Gross profit | Gross profit $22.1b (FY, 2023) | Gross profit $868.6m (FY, 2020) | Gross profit $6.4b (FY, 2023) | Gross profit $13.6b (FY, 2019) | Gross profit kr202b (FY, 2023) | Gross profit $39.8b (FY, 2023) | Gross profit $7.3b (FY, 2023) | Gross profit $2.4b (FY, 2023) | Gross profit N/A | Gross profit $33.9b (FY, 2023) | Gross profit $98.3m (FY, 2023) | Gross profit CHF1b (FY, 2023) |
Net income | Net income $5.7b (FY, 2023) | Net income $197m (FY, 2020) | Net income $54.7m (FY, 2023) | Net income ($5.1b) (FY, 2019) | Net income kr83.7b (FY, 2023) | Net income $6b (FY, 2023) | Net income $1.2b (FY, 2023) | Net income $321.1m (FY, 2023) | Net income N/A | Net income $4.9b (FY, 2023) | Net income ($237.9m) (FY, 2023) | Net income CHF165.7m (FY, 2023) |
Operating ⚠ | ||||||||||||
Countries | Countries N/A | Countries N/A | Countries 165 (Q1, 2023) | Countries 100 (Q1, 2020) | Countries N/A | Countries 130 (FY, 2021) | Countries N/A | Countries 180 (FY, 2023) | Countries N/A | Countries 70 (FY, 2022) | Countries N/A | Countries N/A |
Facilities | Facilities N/A | Facilities N/A | Facilities N/A | Facilities 21 (FY, 2019) | Facilities N/A | Facilities N/A | Facilities N/A | Facilities 200 (FY, 2023) | Facilities N/A | Facilities N/A | Facilities N/A | Facilities N/A |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 13 (FY, 2019) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 45 (FY, 2023) | Manufacturing Facilities N/A | Manufacturing Facilities 19 (FY, 2022) | Manufacturing Facilities N/A | Manufacturing Facilities N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 8 (Q2, 2022) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 1 (FY, 2020) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 9 (Q2, 2022) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2020) | Phase III Trials Products N/A |
Product Categories | Product Categories N/A | Product Categories N/A | Product Categories 3 (Q1, 2023) | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories 6 (FY, 2022) | Product Categories N/A | Product Categories N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 177 (FY, 2021) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 6 (FY, 2020) | Projects in R&D Pipeline N/A |
Funding | ||||||||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 1b | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 174.5m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
PRA Health Sciences
HQ
Raleigh, US
PRA Health Sciences is a contract research organization that provides outsourced clinical development services to the biotechnology and pharmaceutical industries.
View companyViatris
HQ
Canonsburg, US
Employees
38,000↑ 3% increase
Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products.
View companyAllergan
HQ
Dublin, IE
Allergan is a healthcare company focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products.
View companyNovo Nordisk
HQ
Bagsværd, DK
Employees
69,260
Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products.
View company